Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Mol Sci ; 21(11)2020 May 26.
Artículo en Inglés | MEDLINE | ID: mdl-32466601

RESUMEN

A series of new tetrahydroacridine and 3,5-dichlorobenzoic acid hybrids with different spacers were designed, synthesized, and evaluated for their ability to inhibit both cholinesterase enzymes. Compounds 3a, 3b, 3f, and 3g exhibited selective butyrylcholinesterase (EqBuChE) inhibition with IC50 values ranging from 24 to 607 nM. Among them, compound 3b was the most active (IC50 = 24 nM). Additionally, 3c (IC50 for EeAChE = 25 nM and IC50 for EqBuChE = 123 nM) displayed dual cholinesterase inhibitory activity and was the most active compound against acetylcholinesterase (AChE). Active compound 3c was also tested for the ability to inhibit Aß aggregation. Theoretical physicochemical properties of the compounds were calculated using ACD Labs Percepta and Chemaxon. A Lineweaver-Burk plot and docking study showed that 3c targeted both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. Moreover, 3c appears to possess neuroprotective activity and could be considered a free-radical scavenger. In addition, 3c did not cause DNA damage and was found to be less toxic than tacrine after oral administration; it also demonstrated little inhibitory activity towards hyaluronidase (HYAL), which may indicate that it possesses anti-inflammatory properties. The screening for new in vivo interactions between 3c and known receptors was realized by yeast three-hybrid technology (Y3H).


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Clorobenzoatos/química , Inhibidores de la Colinesterasa/síntesis química , Fármacos Neuroprotectores/síntesis química , Tacrina/análogos & derivados , Precursor de Proteína beta-Amiloide/metabolismo , Animales , Dominio Catalítico , Línea Celular Tumoral , Células Cultivadas , Inhibidores de la Colinesterasa/efectos adversos , Inhibidores de la Colinesterasa/farmacología , Inhibidores de la Colinesterasa/uso terapéutico , Colinesterasas/química , Colinesterasas/metabolismo , Depuradores de Radicales Libres/efectos adversos , Depuradores de Radicales Libres/síntesis química , Depuradores de Radicales Libres/farmacología , Depuradores de Radicales Libres/uso terapéutico , Humanos , Hialuronoglucosaminidasa/antagonistas & inhibidores , Ratones , Simulación del Acoplamiento Molecular , Fármacos Neuroprotectores/efectos adversos , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéutico , Unión Proteica , Multimerización de Proteína/efectos de los fármacos
2.
J Mol Med (Berl) ; 99(3): 327-334, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33447926

RESUMEN

Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist. The fundamental role of these receptors is to bind glutamate: the main excitatory neurotransmitter in the brain, believed to play a crucial role in neuronal plasticity and learning mechanisms. Glutamate transmission plays an important role in all internal CNS structures and maintains the physiological state of the brain. Excessive glutamate transmission can lead to enlarged calcium ion current which may cause neurotoxicity; however, insufficient transmission can drastically alter the information flow in neurons and the brain, potentially causing schizophrenia-like symptoms by replacing lost information with completely new stimuli. Hence, it is possible that the modulation of NMDA activity may give rise to pathophysiological states. Available literature and clinical trials indicate that memantine is well tolerated by patients, with very few and light side effects. There is a belief that memantine may also benefit other conditions such as schizophrenia and depression.


Asunto(s)
Antidepresivos/uso terapéutico , Antipsicóticos/uso terapéutico , Depresión/tratamiento farmacológico , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Memantina/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Enfermedad de Alzheimer/tratamiento farmacológico , Antidepresivos/farmacología , Antipsicóticos/farmacología , Ensayos Clínicos como Asunto , Reposicionamiento de Medicamentos , Antagonistas de Aminoácidos Excitadores/farmacología , Ácido Glutámico/fisiología , Humanos , Memantina/farmacología , N-Metilaspartato/fisiología , Plasticidad Neuronal/efectos de los fármacos , Receptores de N-Metil-D-Aspartato/fisiología , Antagonistas del Receptor de Serotonina 5-HT3/farmacología , Antagonistas del Receptor de Serotonina 5-HT3/uso terapéutico
3.
Comput Biol Chem ; 88: 107321, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32622178

RESUMEN

The present study describes the antibacterial activity of several new derivatives of tacrine or cyclopentaquinoline bound to either 6-hydrazinenicotinic acid or 4-fluorobenzoic acid through an aliphatic chain against methicillin-resistant staphylococcal strains. All derivatives showed antibacterial activity against all tested methicillin-resistant staphylococci. Of these, compounds 6, 18, 23 and 24 exhibited the highest activity, ranging from 4.87 to 19.5 µg/mL MBC (Minimum Bactericidal Concentration) depending on the bacterial strain. These values were not much greater than that for vancomycin, the reference standard for the treatment of methicillin-resistant Staphylococci infections in humans. In addition, all synthesized compounds underwent a quantitative structure-activity relationship analysis. Correlation and multicollinearity tests were used to select descriptors as independent variables for multiple linear regression models to quantify the relationships between biological activity and the structural parameters.


Asunto(s)
Acridinas/farmacología , Antibacterianos/farmacología , Resistencia a la Meticilina/efectos de los fármacos , Relación Estructura-Actividad Cuantitativa , Staphylococcus aureus/efectos de los fármacos , Acridinas/síntesis química , Acridinas/química , Antibacterianos/síntesis química , Antibacterianos/química , Humanos , Pruebas de Sensibilidad Microbiana , Estructura Molecular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA